MTPConnect and The Australian Cardiovascular Alliance (ACvA), alongside ACvA members Sydney University’s Charles Perkins Centre and the Victor Chang Cardiac Research Institute, have combined efforts to boost Australia’s clinical trial sector.
[Sydney, NSW; July 2nd 2021] A Sydney start-up hopes to harness Australia’s capacity for innovating Cardiovascular technologies. Initially supported by a group led by the federal Government’s Growth Centre for medical technologies, MTPConnect, the non-for-profit is developing a Shop Window for the industry alongside concierge, ethics and study management support services.
Recently launched as Ventri Clinical, the project is being hosted by the Australian Cardiovascular Alliance (ACvA), who count University of Sydney’s Professor Gemma Figtree, ex-Heart Foundation NSW Chief Kerry Doyle and Victor Chang Executive Jason Kovacic among their leadership.
Ventri Clinical hopes to target sponsors of early-stage clinical development, pilot and post-market studies for the full range of cardiology technologies, including interventional devices, electrophysiology, diagnostics and echocardiography.
“This is a unique opportunity to connect and empower a relatively disparate niche in Australia”, notes Anthony Murray, Ventri’s Director. “We clearly punch above our weight when it comes to outstanding physicians, clinical sites and study services, so the support from the ACvA’s board and Australian medical device industry carries a lot of weight. There are skills gaps and we’re aiming to help fill them.”
“We’ve had a great response from cardiovascular specialists already and looking for investigators, clinical sites, contractors, engineers, health economists and CROs with experience in conducting or contributing to successful studies.”
More Australians die of Heart Disease than any other cause, claim the Heart Foundation, so it’s no surprise Kerry Doyle is behind the project. “Ventri Clinical’s long-term strategy is to improve health outcomes by making it far easier to engineer, test and market devices that will change lives. The fact that Australia may host better connected trials along the way is a win-win.”
Service providers keen on collaborating should get in touch with Ventri Clinical directly, as should any study sponsors looking to make the most of Australia’s rich talent in Cardiovascular innovation.
For more information, please reach: Anthony Murray, Anthony@VentriClinical.Org and +61 404 376 967.
Ventri Clinical is a new, Non-For-Profit clinical network, connecting Australia’s capability and capacity for successful clinical studies in Cardiovascular medical devices. Facilitated by the Australian Cardiovascular Alliance (ACvA) and backed by MTPConnect, Australia's Growth Centre for the medical technologies, Ventri Clinical connects clinicians, sites and service providers through the industry’s shop window. Trial sponsors use Ventri Clinical for concierge and project management of Cv medtech studies in Australia.
Established in 2015, the Australian Cardiovascular Alliance (ACvA) aims to increase the visibility of cardiovascular disease as a National Health Priority Area in the Australian community and in government. Specifically, the ACvA:
Acts as advocate for increased peer-reviewed funding in heart, stroke and vascular disease research.
Represents cardiovascular researchers calling for more research into heart, stroke and vascular disease.
Promotes the development of strong collaborative networks between cardiovascular researchers Australia-wide.